Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR; COVID-OUT Study Team.
Bramante CT, et al.
Lancet Infect Dis. 2023 Oct;23(10):1119-1129. doi: 10.1016/S1473-3099(23)00299-2. Epub 2023 Jun 8.
Lancet Infect Dis. 2023.
PMID: 37302406
Free PMC article.
Clinical Trial.
The median age was 45 years (IQR 37-54) and median BMI was 29.8 kg/m(2) (IQR 27.0-34.2). Overall, 93 (8.3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. ...
The median age was 45 years (IQR 37-54) and median BMI was 29.8 kg/m(2) (IQR 27.0-34.2). Overall, 93 (8.3%) of 1126 participants repo …